Dario Prais

Also affiliated with Schneider Children's Medical Center

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials”.

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00411-9

N/A

1.9DataRank · unranked

95 citations

Lael M. Yonker, F. Vermeulen, Dario Prais, Rachel W. Linnemann, Aaron Trimble +92 more

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine(2022)10.1164/rccm.202202-0392oc

N/A

0DataRank · unranked

141 citations

Rossa Brugha, Silvia Gärtner, Julian Legg, Alexander Mœller, Pedro Mondéjar-López +19 more